PharmaEngine, Inc. (TPEX:4162)

Market Cap	11.02B
Revenue (ttm)	2.55B
Net Income (ttm)	1.77B
Shares Out	143.68M
EPS (ttm)	12.31
PE Ratio	6.23
Forward PE	32.09
Dividend	6.00 (7.70%)
Ex-Dividend Date	Aug 13, 2025

Volume	1,315,267
Average Volume	734,768
Open	77.10
Previous Close	76.70
Day's Range	76.50 - 79.20
52-Week Range	72.30 - 123.00
Beta	0.27
RSI	50.92
Earnings Date	Jul 29, 2025

About Silk Road Medical

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 44
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2024, PharmaEngine's revenue was 2.52 billion, an increase of 228.70% compared to the previous year's 767.67 million. Earnings were 1.75 billion, an increase of 537.55%.